Silver Oak Securities Incorporated Has $459,000 Position in Amgen Inc. (NASDAQ:AMGN)

Silver Oak Securities Incorporated lowered its holdings in Amgen Inc. (NASDAQ:AMGN) by 12.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,423 shares of the medical research company’s stock after selling 210 shares during the quarter. Silver Oak Securities Incorporated’s holdings in Amgen were worth $459,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Hershey Financial Advisers LLC acquired a new position in Amgen in the second quarter worth $30,000. nVerses Capital LLC acquired a new position in Amgen in the second quarter worth $31,000. Bbjs Financial Advisors LLC acquired a new position in Amgen in the second quarter worth $33,000. Matrix Trust Co acquired a new position in Amgen in the third quarter worth $36,000. Finally, FSA Wealth Management LLC boosted its stake in Amgen by 182.0% in the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of several research reports. Dbs Bank raised Amgen to a “strong-buy” rating in a research note on Monday, September 16th. TD Cowen upped their price target on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Sanford C. Bernstein initiated coverage on Amgen in a research note on Thursday, October 17th. They set an “outperform” rating and a $380.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $380.00 price target on shares of Amgen in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $332.55.

Amgen Stock Up 0.4 %

Shares of Amgen stock opened at $316.98 on Friday. Amgen Inc. has a 1 year low of $249.70 and a 1 year high of $346.85. The business has a 50-day moving average of $325.49 and a two-hundred day moving average of $313.77. The company has a market capitalization of $170.04 billion, a P/E ratio of 45.28, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.35 billion. During the same quarter last year, the company earned $5.00 earnings per share. The firm’s revenue was up 20.1% compared to the same quarter last year. As a group, equities analysts predict that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.84%. Amgen’s dividend payout ratio (DPR) is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.